Form 4: Cryo-Cell Co-CEO Portnoy Reports New Stock Option Grants

Cryo-Cell International Co-CEO Mark L. Portnoy reported new stock option grants and updated his beneficial ownership, including performance-based vesting conditions.

Summary

• Mark L. Portnoy, Co-CEO, Director, and 10% Owner of Cryo-Cell International Inc. (CCEL), filed a Form 4 to report changes in his beneficial ownership.
• On January 7, 2026, Mr. Portnoy was granted 50,000 stock options with an exercise price of $3.89 per share, pursuant to the Cryo-Cell 2022 Stock Incentive Plan.
• These 50,000 options are divided into three equal tranches, each subject to both time-based vesting (first, second, and third anniversaries of the grant date) and stock-price performance conditions (average closing price of at least $6, $8, and $10 per share over 20 consecutive trading days, respectively).
• Additionally, on January 7, 2026, Mr. Portnoy was granted 25,000 stock options with an exercise price of $3.89 per share, vesting 1/3 upon issuance, 1/3 on January 7, 2027, and 1/3 on January 7, 2028.
• Mr. Portnoy's direct beneficial ownership of common stock is 821,973 shares.
• His indirect beneficial ownership includes 42,266 shares held by his 401K and 71,529 shares held by Capital Asset Fund #1 Limited Partnership, where he is deemed a beneficial owner as its general partner.
• He also holds various other stock options from previous grants with different exercise prices and vesting schedules, including 100,000 options that vest immediately if the stock price reaches $25.00 per share.

Sentiment

Score: 7

Explanation: The filing reports new stock option grants to a key executive, including performance-based vesting, which generally aligns management incentives with shareholder value. This is a standard disclosure and not inherently negative, but also not a direct indicator of immediate operational success.

Positives

• The grant of new stock options to a Co-CEO, particularly those with performance-based vesting conditions tied to stock price targets ($6, $8, $10), aligns management incentives directly with shareholder value creation.
• The existence of stock options with a high vesting trigger ($25.00 per share) indicates a long-term growth aspiration for the company's stock price.

Risks

• The vesting of a significant portion of the stock options is contingent on the company's common stock reaching specific price targets ($6, $8, $10, $25), which introduces market performance risk for the options to fully vest and become valuable.
• The value of the stock options is subject to the future market price of Cryo-Cell International's common stock, which can fluctuate.

Future Outlook

The performance-based vesting conditions for some stock options, requiring the company's common stock to reach specific price targets of $6, $8, $10, and $25 per share, imply management's expectation or goal for future stock price appreciation and long-term value creation.

Management Comments

• Mark L. Portnoy, Co-CEO, Director, and 10% Owner, reported changes in his beneficial ownership, including the grant of new stock options with both time-based and performance-based vesting conditions.

Industry Context

Form 4 filings are standard disclosures for insiders of publicly traded companies, reflecting changes in their ownership. The granting of stock options is a common practice in the biotechnology and healthcare sectors (Cryo-Cell is a stem cell storage company) to incentivize executives and align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of stock options with performance-based vesting, tied to specific stock price targets, is a common executive compensation strategy across various industries, including biotech, to align management incentives with shareholder returns.
• The structure of vesting over multiple years and tranches is consistent with typical long-term incentive plans designed to retain executives and encourage sustained performance.

Corporate Governance

Related Party Transactions

• Shares of common stock are held indirectly by Capital Asset Fund #1 Limited Partnership, as to which Mark Portnoy may be deemed a beneficial owner as its general partner.

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of executive incentives with stock performance, encouraging management to drive share value.
• Management/Employees: Mark L. Portnoy's compensation package is enhanced with long-term equity incentives, potentially strengthening his commitment and retention.

Next Steps

• Continued service of Mark L. Portnoy to the company is required for the time-based stock options to vest.
• Achievement of specific stock price targets ($6, $8, $10, $25 per share) is necessary for the performance-based stock options to vest.

Key Dates

Recommendation

This Form 4 filing primarily details changes in insider beneficial ownership and the grant of new stock options to a Co-CEO. While the performance-based vesting conditions for some options suggest management's confidence and align incentives, this is a routine disclosure and does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change from a 'hold' position. It confirms ongoing executive compensation practices.

Keywords

Cryo-Cell International, CCEL, Form 4, Insider Ownership, Stock Options, Executive Compensation, Mark L. Portnoy, Co-CEO, Beneficial Ownership, Performance-based vesting, Equity compensation